Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
31 hedge funds and large institutions have $27.2M invested in Zynerba Pharmaceuticals, Inc in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
29% more funds holding
Funds holding: 24 → 31 (+7)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
20% less capital invested
Capital invested by funds: $34.1M → $27.2M (-$6.86M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.38M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.73M |
| 3 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
+$644K |
| 4 |
State Street
Boston,
Massachusetts
|
+$491K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$462K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$2.24M |
| 2 |
PA
Perceptive Advisors
New York
|
-$277K |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$236K |
| 4 |
SIM
Spark Investment Management
New York
|
-$176K |
| 5 |
Morgan Stanley
New York
|
-$87.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $6.44K | – | – | – |
|
|
CCA
27
Catalyst Capital Advisors
Huntington,
New York
| $4K | +$4.61K | +348 | New |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $1K | -$1.83K | -138 | -69% |
|
29
Wells Fargo
San Francisco,
California
| $1K | -$93 | -7 | -6% |
|
|
LTFS
30
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
31
Bank of America
Charlotte,
North Carolina
| $1K | +$1.1K | +83 | New |
|
|
HCMT
32
Highland Capital Management (Texas)
Dallas,
Texas
| – | -$2.24M | -156,547 | Closed |
|
|
SIM
33
Spark Investment Management
New York
| – | -$176K | -12,335 | Closed |
|
34
Norges Bank
Oslo,
Norway
| – | -$72K | -5,000 | Closed |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -100 | Closed |
|
ZYNE Hedge Fund Activity: Q4 2015 in Review
31 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2015, worth a combined $27.2M — down 20% from $34.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ZYNE positions and 4 closed out — a net gain of 7 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $2.38M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $2.24M sold.
- 31 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2015, up from 24 in Q3 2015.
- Funds reported $27.2M of Zynerba Pharmaceuticals, Inc stock for Q4 2015, down 20% quarter-over-quarter.
- 11 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2015 and 4 closed out, a net change of +7 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2015 was JP Morgan Chase, an estimated $2.38M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2015 was Highland Capital Management (Texas), an estimated $2.24M sold.
Based on aggregated 13F filings for Q4 2015.